Sun Pharma Q4 PAT may dip 18.1% YoY to Rs. 1,000 cr: HDFC Securities

HDFC Securities has come out with its fourth quarter (Jan-March’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Sun Pharma to report net profit at Rs. 1,000 crore down 18.1% year-on-year (up 14.1% quarter-on-quarter).

Net Sales are expected to decrease by 5.1 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs. 6,780 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 0.3 percent Y-o-Y (up 6.1 percent Q-o-Q) to Rs. 1,540 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.